Development
GSK plc
GSK
$37.68
$0.120.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -76.55% | -8.82% | 12.36% | 3.04% | -86.22% |
| Total Depreciation and Amortization | 5.56% | 29.57% | -27.20% | 559.49% | -115.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 655.58% | -11.14% | -222.79% | -95.84% | 116.09% |
| Change in Net Operating Assets | 553.67% | 137.93% | 66.94% | -95.56% | -16,261.11% |
| Cash from Operations | 41.75% | 71.19% | 2,442.11% | -97.12% | 43.86% |
| Capital Expenditure | -59.47% | -2.18% | -30.96% | 45.00% | -58.89% |
| Sale of Property, Plant, and Equipment | -37.57% | 270.88% | -55.82% | -94.56% | 1,795.44% |
| Cash Acquisitions | 96.89% | 95.45% | -144,421.75% | 98.75% | 97.27% |
| Divestitures | -243.37% | -103.16% | 1,199.58% | 74.15% | -242.03% |
| Other Investing Activities | 637.46% | -120.93% | 492.90% | -41.35% | 83.77% |
| Cash from Investing | 153.55% | 48.48% | -143.56% | 21.89% | 86.84% |
| Total Debt Issued | -129.11% | -136.28% | 207.07% | -55.23% | 51.66% |
| Total Debt Repaid | -191.93% | 31.59% | -269.63% | 88.71% | 15.99% |
| Issuance of Common Stock | -- | -100.00% | -62.50% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 1.72% | -2.97% | -3.46% | 12.26% | 7.46% |
| Other Financing Activities | -112.37% | 75.99% | -210.77% | 42.22% | -139.34% |
| Cash from Financing | -100.00% | -5,849.23% | 110.05% | 75.43% | -0.66% |
| Foreign Exchange rate Adjustments | -245.03% | 140.81% | -89.54% | -169.67% | 99.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -782.98% | -105.74% | 146.42% | -1,097.04% | 101.79% |